Kala Pharmaceuticals reports Q3 EPS ($1.93) vs ($3.41) last year

“We remain focused on advancing patient enrollment in our Phase 2b CHASE trial evaluating KPI-012 for the treatment of PCED and are targeting topline results in the second quarter of 2025,” said Mark Iwicki, Chair and Chief Executive Officer of KALA BIO. “We believe KPI-012 has the potential to be a first-in-class treatment for PCED with the potential to address all underlying etiologies of this debilitating condition and provide a treatment option for a broad population of PCED patients. If successful, this trial may serve as the first of two pivotal trials in support of a BLA submission that could potentially revolutionize treatment options for patients with PCED.”